Cardiovascular and Metabolic Archives | Report Store

Diabetes and diabetic complications
Other metabolic diseases
Anemias
Hypertension
Thrombosis
Bleeding disorders
Cerebrovascular diseases
Heart failure
Ischemic heart disease

Text search

Sort by Custom

Click to order products ascending

Display 15 Products per page

2019 Post-ADA Report

$2,995.00

The American Diabetes Association (ADA) 79th Scientific Sessions was held in San Francisco, CA from 7–11 June 2019.

July 22, 2019
Find out more
Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – France

$599.00

This interview with a French key opinion leader (KOL) provides insight into pipeline therapies for non-alcoholic steatohepatitis (NASH), as well as pricing strategies and future treatment rates for the different fibrosis stages of NASH.
May 20, 2019
Find out more
Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US

$599.00

This interview with a US key opinion leader (KOL) provides insight into pipeline therapies for non-alcoholic steatohepatitis (NASH), as well as pricing strategies, diagnostic tools, and future treatment rates for the different fibrosis stages of NASH. Key pipeline assets highlighted include Ocaliva, elafibranor, cenicriviroc, and firsocostat.
May 20, 2019
Find out more
Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Reimbursement

$599.00

This reimbursement interview with a US key opinion leader (KOL) provides insight into pricing strategies, pricing barriers, and potential reimbursement criteria for non-alcoholic steatohepatitis therapies.
May 20, 2019
Find out more
Diabetes Management: Blood Glucose Monitoring Devices Market

$4,750.00

According to the International Diabetes Federation (IDF), approximately 425 million adults (20-79 years of age) have diabetes worldwide, and this number is expected to rise nearly 50% to approximately 629 million by 2045. More than 1.25 million people have type 1 diabetes in the US alone.
December 19, 2019
Find out more
Diabetes Management: Blood Glucose Monitoring Devices Market (2021)

$4,750.00

This report provides a detailed presentation of diabetes and blood glucose monitoring devices, including standard fingerstick-based blood glucose meters (BGMs) and new sensor-based continuous glucose monitoring systems (CGMs) that attach to the body and monitor blood glucose 24 hours a day
March 31, 2021
Find out more
Diabetes Management: Insulin Pumps Market (2019)

$4,750.00

This report provides an overview of diabetes, automated insulin pump systems, and a comprehensive market and competitive analysis.
September 30, 2019
Find out more
Diabetes Management: Insulin Pumps Market (2020)

$4,750.00

This report provides an overview of diabetes, automated insulin pump systems, and a comprehensive market and competitive analysis.
December 30, 2020
Find out more
Digital Health: Diabetes Apps and Virtual Coaching

$2,250.00

Smartphone-based digital health technologies are expected to transform the diabetes management market over the next decade by substantially improving diabetes outcomes and reducing healthcare costs. These technologies are engaging and empowering patients, improving glycemic control, and lowering complications. Digital health technologies are defined in this report as: diabetes smartphone apps integrated with blood glucose monitoring devices (both standard blood glucose meters and continuous glucose monitoring systems) and personalized “virtual diabetes coaching” services.
March 10, 2020
Find out more
Disease Analysis: Anemia in Chronic Kidney Disease
Read More
Anemia in chronic kidney disease (CKD), defined as a reduction in red blood cells (RBCs) or hemoglobin levels, often results from decreased levels of erythropoietin and increased levels of hepcidin. Erythropoietin is primarily produced in the kidneys and increases the production of RBCs by acting on precursor cells. H
June 7, 2022
Find out more
Disease Analysis: Chronic Heart Failure
Read More
Chronic heart failure (CHF) is a progressive condition in which the heart muscle is unable to pump enough blood to meet the needs of the body. CHF can result from functional abnormalities such as ventricular dysfunction or arrhythmias, or structural disorders of the myocardium or valves.
June 30, 2022
Find out more
Disease Analysis: Diabetic Nephropathy
Read More
Diabetic nephropathy, also known as diabetic kidney disease, is caused by damage to small blood vessels which can cause the kidneys to be less efficient in their blood filtration role or to fail altogether.
March 11, 2022
Find out more
Disease Analysis: Dyslipidemia
Read More
Dyslipidemia refers to any increase or decrease in lipid levels from defined normal parameters, with physicians particularly focusing on the treatment of elevated low-density lipoprotein cholesterol (LDL-C) due to the well-established link between excessively elevated LDL-C and atherosclerosis. As such, LDL-C is a major modifiable risk factor for cardiovascular (CV) disease, one of the world’s leading causes of morbidity and mortality, though differences in LDL particle morphology can also play a role. Other lipid level deviations in dyslipidemia include elevated triglycerides, low levels of high-density lipoprotein cholesterol (HDL-C), elevated total cholesterol, and elevated non-HDL-C, a marker of cholesterol in all atherogenic lipoproteins
May 13, 2022
Find out more
Disease Analysis: Hemophilia
Read More
Hemophilia is a rare, inherited X chromosome-linked bleeding disorder in which deficiencies in clotting factors prevent blood from clotting normally. Injuries therefore result in prolonged periods of bleeding. There are two types of hemophilia, A and B, with similar signs and symptoms but different genetic defects.
February 25, 2022
Find out more
Disease Analysis: Non-Alcoholic Steatohepatitis (NASH)
Read More
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of patients who have fatty liver in the absence of significant alcohol consumption. NAFLD patients are often segmented into non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) patients. NAFLD diagnosis requires evidence of hepatic steatosis and lack of secondary causes of liver fat accumulation such as substantial alcohol consumption, long-term use of a steatogenic medicine, or monogenic hereditary disorders. NASH is defined as the presence of >5% hepatic steatosis and inflammation with hepatocyte injury, with or without fibrosis. Although the presence of fibrosis is not required for a diagnosis of NASH, fibrosis is present in over 80% of NASH patients. For this reason, NASH patients are often further segmented by their fibrosis stage.
February 23, 2022
Find out more

Cardiovascular and Metabolic

2019 Post-ADA Report

Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – France

Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US

Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Reimbursement

Diabetes Management: Blood Glucose Monitoring Devices Market

Diabetes Management: Blood Glucose Monitoring Devices Market (2021)

Diabetes Management: Insulin Pumps Market (2019)

Diabetes Management: Insulin Pumps Market (2020)

Digital Health: Diabetes Apps and Virtual Coaching

Disease Analysis: Anemia in Chronic Kidney Disease

Disease Analysis: Chronic Heart Failure

Disease Analysis: Diabetic Nephropathy

Disease Analysis: Dyslipidemia

Disease Analysis: Hemophilia

Disease Analysis: Non-Alcoholic Steatohepatitis (NASH)